Irish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Die Pharmazie 2013-Jul

Molecular determinants of cancer cell sensitivity and resistance towards the sesquiterpene farnesol.

Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
Sábháiltear an nasc chuig an gearrthaisce
V Kuete
T Efferth

Keywords

Coimriú

Farnesol is a non-cyclic sesquiterpene (isoprenoid) found in the essential oils of many plants. In cancer biology, farnesylation of mutated Ras oncoproteins allows the proteins to dock to the membrane and be functionalized. Therefore, farnesyltransferase is a target for drug development to inhibit Ras. Farnesol exhibits cytotoxic activity against tumor cells in vitro and in vivo, implying that novel treatment strategies may be devised independent of Ras farnesylation. Tumors frequently develop resistance towards standard chemotherapies, and thus novel agents are urgently required that bypass the cross-resistance evoked by established anticancer drugs. We investigated whether classical mechanisms of drug resistance such as ATP-binding cassette transporters (P-glycoprotein/MDR1, MRP1, BCRP), the tumor suppressor gene TP53, and the oncogene EGFR play a role in the response of tumor cells to farnesol. Remarkably, none of these genes conferred resistance to farnesol, indicating that this compound may be useful for the treatment of otherwise drug-resistant and refractory tumors expressing these mechanisms of resistance. Furthermore, we applied a pharmacogenomic approach to explore molecular determinants of sensitivity and resistance to farnesol. Among the candidates were genes involved in apoptosis (STAB2, NUMBL), regulation of transcription (CDYL, FOXA2) and diverse other functional groups (INE1, CTRL, MRS2, NEB, LMO7, C9orf3, EHBP1). The fact that these genes are not associated with resistance to traditional anticancer drugs suggests farnesol may possess a novel mechanism of action, and consequently might bypass drug resistance to established chemotherapeutics.

Bí ar ár
leathanach facebook

An bunachar luibheanna míochaine is iomláine le tacaíocht ón eolaíocht

  • Oibreacha i 55 teanga
  • Leigheasanna luibhe le tacaíocht ón eolaíocht
  • Aitheantas luibheanna de réir íomhá
  • Léarscáil GPS idirghníomhach - clibeáil luibheanna ar an láthair (ag teacht go luath)
  • Léigh foilseacháin eolaíochta a bhaineann le do chuardach
  • Cuardaigh luibheanna míochaine de réir a n-éifeachtaí
  • Eagraigh do chuid spéiseanna agus fanacht suas chun dáta leis an taighde nuachta, trialacha cliniciúla agus paitinní

Clóscríobh symptom nó galar agus léigh faoi luibheanna a d’fhéadfadh cabhrú, luibh a chlóscríobh agus galair agus comharthaí a úsáidtear ina choinne a fheiceáil.
* Tá an fhaisnéis uile bunaithe ar thaighde eolaíoch foilsithe

Google Play badgeApp Store badge